Education
About Us
Working with TipRanks
Follow Us
Icecure Medical Ltd. (ICCM)
:ICCM
ICCM Stock Chart & Stats
$0.86
-$0.06(-4.41%)
At close: 4:00 PM EST
$0.86
-$0.06(-4.41%)
Day’s Range― - ―
52-Week Range$0.55 - $1.63
Previous CloseN/A
Volume318.06K
Average Volume (3M)1.69M
Market Cap
$48.96M
Enterprise Value$55.42M
Total Cash (Recent Filing)$5.38M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
Nov 25, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,693,054
10 Day Avg. Volume443,467
30 Day Avg. Volume1,691,182
Financial Highlights & Ratios
PEG Ratio0.58
Price to Book (P/B)8.11
Price to Sales (P/S)17.01
P/FCF Ratio-4.43
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue19.89
Enterprise Value/Gross Profit55.36
Enterprise Value/Ebitda-3.57
Forecast
1Y Price Target
$2.75Price Target Upside219.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.22
Revenue Forecast (FY)$3.32M
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageProSense is the first and only medical device cleared by the FDA for local treatment of breast cancer, creating a market entry barrier for competitors.
Market ExpansionGrowing traction in European markets, supported by positive clinical data, indicates strong potential for international expansion.
Regulatory ApprovalThe FDA's decision to grant marketing authorization for ProSense in the treatment of early-stage, low-risk breast cancer is a significant positive milestone for IceCure Medical Ltd.
Bears Say
Post-Market SurveillanceThe FDA has requested a post-market surveillance study, requiring IceCure to conduct additional research with 400 patients at 30 sites.
Revenue DeclineRevenue was $525K, representing 48% YoY decline and missing the projection of $800K.
Supply Chain DisruptionShipments of product sales worth more than $200K were delayed due to the Israel-Iran conflict.
Icecure Medical News
ICCM FAQ
What was Icecure Medical Ltd.’s price range in the past 12 months?
Icecure Medical Ltd. lowest stock price was $0.55 and its highest was $1.63 in the past 12 months.
What is Icecure Medical Ltd.’s market cap?
Icecure Medical Ltd.’s market cap is $48.96M.
When is Icecure Medical Ltd.’s upcoming earnings report date?
Icecure Medical Ltd.’s upcoming earnings report date is Nov 25, 2025 which is in 8 days.
How were Icecure Medical Ltd.’s earnings last quarter?
Icecure Medical Ltd. released its earnings results on Aug 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.064 by $0.004.
Is Icecure Medical Ltd. overvalued?
According to Wall Street analysts Icecure Medical Ltd.’s price is currently Undervalued.
Does Icecure Medical Ltd. pay dividends?
Icecure Medical Ltd. does not currently pay dividends.
What is Icecure Medical Ltd.’s EPS estimate?
Icecure Medical Ltd.’s EPS estimate is -0.05.
How many shares outstanding does Icecure Medical Ltd. have?
Icecure Medical Ltd. has 68,693,054 shares outstanding.
What happened to Icecure Medical Ltd.’s price movement after its last earnings report?
Icecure Medical Ltd. reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.064. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of Icecure Medical Ltd.?
Currently, no hedge funds are holding shares in ICCM
Icecure Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.75 (219.77% Upside)
$2.75 (219.77% Upside)
Hedge Fund Trend
Decreased
By 11.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days <0.1%
Last 30 Days <0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.18%
12-Months-Change
Fundamentals
Return on Equity
-230.80%
Trailing 12-Months
Asset Growth
-31.06%
Trailing 12-Months
Company Description
Icecure Medical Ltd.
Icecure Medical (ICCM) is a medical device company specializing in innovative cryoablation solutions for the treatment of tumors. The company focuses on the development and commercialization of its proprietary technology, the ProSense system, which utilizes precise cryotherapy to target and destroy cancerous tissues. Operating primarily in the healthcare sector, Icecure Medical aims to enhance patient outcomes while providing minimally invasive treatment options across various types of tumors, including breast and liver cancers.
ICCM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights strong regulatory progress and clinical achievements, particularly with ProSense's anticipated FDA approval and significant adoption in Europe and Japan. However, these positives are tempered by financial challenges, including decreased revenue, gross profit, and continued net losses, partly due to geopolitical issues.View all ICCM earnings summariesICCM Stock 12 Month Forecast
Average Price Target
$2.75
▲(219.77% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.06% Mutual Funds
<0.01% Other Institutional Investors
99.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---